Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report

Abstract

Eribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our knowledge, information on its use in dialytic patients is not available to date. This report describes the case of a chemo-pretreated dialytic woman with lung, bone, and liver metastasis from breast cancer, who experienced stable disease with a response < 20% with eribulin in fifth line after 3 hormonal lines and 1 chemotherapy line. This case suggests the feasibility and good tolerability of eribulin in this peculiar setting.